Fred Hutch, Seattle Cancer Care Alliance, and UW Medicine Complete Restructure of Partnership

Learn More

CCRC Clinical Studies

Potential study participants talking with nurse

Advancing COVID-19 Clinical Research

 
The CCRC researchers are focused on the advancement of effective therapeutics and interventions for COVID-19 and hope to further the develop treatment and prevention that could be accessible for community members locally and globally, outside of a hospital setting.

The CCRC research teams have conducted a wide range COVID-related clinical studies, including treatment and prophylaxis use of monoclonal antibody infusions/injections and oral antiviral medications. The research participation opportunities that are open for enrollment and that have previously taken place at the CCRC are detailed below for reference. Study sponsors cover all clinical study-related costs. The CCRC is not a hospital and will only have participation from volunteers that fit the study criteria and fully consent to participation.

 Interested in volunteering for one of our studies? Contact us to see if you qualify.

Your Health is Our Priority

The COVID-19 Clinical Research Center has been designed with safety top of mind with separate entrances and exits for study volunteers, optimized medical-grade air flow, private clinic rooms, extensive cleaning & disinfecting protocols and more. If you are chosen to join a study, your health will be closely monitored and care adjusted if our team determines that it is in your best interest. You may also end the study at any time without having to provide a reason.

Qualifying for Our Studies

Our studies are inclusive of adult participants of all races, ethnicities, and backgrounds to help Researchers understand the best treatment medicines and methods across diverse populations. The facility plans to support COVID-positive study participants as well as those that have recently recovered from COVID infection. Each study has different criteria for participation. Review each study listed below for more information on the eligibility criteria.

About Informed Consent

Before you participate in a study, our researchers will make sure you understand the details of the study and all of the possible known benefits, risks and alternatives to the trial in a process known as informed consent. This time will help you learn the facts about the study before deciding to take part in the trial. Informed consent is not a contract and you always have a right to ask our team questions or end your involvement at any time during the trial. 

Current Studies — Open For Enrollment

molnupiravir MK-4482-013 — Merck Sharp & Dohme Corp.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19.


Study Purpose and Summary

The primary objectives of this phase 3, multicenter, randomized, double-blind, placebo-controlled study are to determine the efficacy, and safety/tolerability, of molnupiravir (MK-4482) in adults who reside with a person infected with COVID-19. It is hypothesized that molnupiravir is superior to placebo in preventing laboratory-confirmed COVID-19 infection through Day 14 in participants (regardless of baseline viral test result) who do not have confirmed or suspected COVID-19 at time of screening and randomization.


Eligibility Criteria

  • Adults 18 years of age or older
  • Willing and able to provide written informed consent to participate
  • Are residing with a person that has tested positive for COVID-19 infection within the past 5 days
  • Cannot test positive for SARS-CoV-2 or have symptoms at time of enrollment
  • Cannot have been vaccinated
  • Able to swallow small pills
  • Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period

Other protocol-defined Inclusion/Exclusion criteria may apply.


More about this trial

Visit ClinicalTrials.gov, identifier NCT04939428, to determine if this study is right for you.

Resolve RSLV-132 — Resolve Therapeutics LLC.

A phase 2, double-blind, placebo-controlled study of RSLV-132 in subjects with post-acute COVID-19 (long COVID).


Study Purpose and Summary

The purpose of this study is to assess the efficacy (decrease in severe fatigue), safety, and pharmacokinetics of RSLV-132 in subjects with post-acute COVID (long COVID) syndrome. RSLV-132 is administered by intravenous infusion (IV) and is an enzymatically active ribonuclease designed to digest the ribonucleic acid contained in autoantibodies and immune complexes, and thereby render them biologically inert.


Eligibility Criteria

  • Adults 18-75 years of age
  • Willing and able to provide written informed consent to participate
  • Tested positive for SARS-CoV-2 (COVID-19 infection) at least 24 weeks prior to enrollment
  • Experiencing long-haul profound fatigue as a result from COVID-19 infection
  • Scoring at least 21 for PROMIS Fatigue Short Form 7a 
  • Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period

Other protocol-defined Inclusion/Exclusion criteria may apply.


More about this trial

Visit ClinicalTrials.gov, identifier NCT04944121, to determine if this study is right for you.

DVX201 — Deverra Therapeutics, Inc.

A Phase 1 Study of DVX201, an Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19


Study Purpose and Summary

This study is a Phase 1 study to determine the highest tolerated dose of an investigational cell therapy called DVX201 in patients hospitalized with COVID-19. DVX201 is an allogeneic NK (natural killer) cell therapy. NK cells are a normal part of your immune system that have the ability to identify and kill cells in the body that are infected by viruses such as COVID-19. There is evidence that both NK cell exhaustion and low numbers of NK cell in the blood occur in COVID-19 patients, and this may contribute to worsening of the infection. Therefore, infusion of healthy functional NK cells (like DVX201).


Eligibility Criteria

  • Adults 18-80 years of age
  • Willing and able to provide written informed consent to participate
  • Tested positive for SARS-CoV-2/COVID-19 (test occurred not more than 7 days prior to enrollment)
  • Experiencing at least one of the symptoms common of COVID-19 (onset no more than 7 days prior to enrollment)
  • Current hospitalization at UW Medical Center - Montlake or Harborview, and meet the following:
    • Radiographic infiltrates by imaging
    • Able to maintain a SpO2 > 93% at rest
    • Meet 2 out of the 3 following criteria: i. IL-6 < 150 pg/mL ii. CRP < 100 mg/L (10 mg/dL) iii. Ferritin < 1000 ng/mL
  • Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period

    Other protocol-defined Inclusion/Exclusion criteria may apply.


More about this trial

Visit ClinicalTrials.gov, identifier NCT04668950, to determine if this study is right for you

Fred Hutch is also seeking volunteers for observational and vaccine trials for COVID-19.

Past Studies — No Longer Enrolling

casirivimab+imdevimab REGN-2176 - Regeneron Pharmaceuticals, Inc

A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of anti-spike SARS-CoV-2 monoclonal antibodies as pre-exposure prophylaxis to prevent COVID-19 in immunocompromised participants.


This study’s primary objective was to evaluate the effect of casirivimab + imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants. .

molnupiravir MK-4482-002 — Merck Sharp & Dohme Corp.

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19.


This study aimed to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. This study enrolled adults who had recently tested positive for SARS-COV-2 and had experienced at least one related mild or moderate symptom. Patients between the ages of 18-59 were required to have at least one pre-existing risk factor to be eligible.

 

sotrovimab VIR COMET TAIL — Vir Biotechnology Inc

A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the treatment of mild/moderate coronavirus disease 2019 (COVID-19) in high-risk non-hospitalized patients


This was a phase 3 study that compared the administration route of an intramuscular shot to IV infusion of sotrovimab, a monoclonal antibody with FDA emergency use authorization, for the early treatment of non-hospitalized patients with COVID-19.

REGN 2067 — Regeneron Pharmaceuticals

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19


The REGN 2067 study tested an infusion of REGN-COV2, a combination of two antibodies against SARS-CoV-2, the virus that causes COVID-19, to see whether they could: decrease the amount of virus in the body; decrease the length of time the virus is in the body; and decrease the length and severity of COVID-19 illness.

Remdesivir — Gilead Sciences, Inc

A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting


The primary objectives of this study were to evaluate the efficacy of remdesivir (RDV) in reducing the rate of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.

StopCOVID2 — Washington University School of Medicine, St Louis

Fluvoxamine for Early Treatment of COVID-19: A Fully-remote, Randomized Placebo Controlled Trial


The purpose of this research study was to determine if a drug called fluvoxamine could be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder. The use of fluvoxamine for the treatment of COVID-19 was considered investigational, which means the US Food and Drug Administration has not approved it for this use. This study was fully-remote, which means that there is no face-to-face contact; study materials including study drug were shipped to participants' houses. People around the United States and Canada could participate.

EIDD 2801 — Ridgeback Therapeutics

This is a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 versus placebo as measured by infectious virus detection in symptomatic adult outpatients with COVID-19.


This study was Phase 2 of Merck’s MK-4482-002 study, under Ridgeback Therapeutics. Preliminary results show a reduction in infection time with no adverse events reported that were study drug related.

COVID-19 Clinical Research Center

Entrance A:
820 Minor Ave N.
Seattle, WA 98109
Directions

Entrance B:
1205 Aloha St.
Seattle, WA 98109
Directions

Phone: 206.667.7100
Work Location: 820 Minor Ave N. Seattle, WA 98109